论文部分内容阅读
目的 研究新药吗氯贝胺的药代动力学 ,抗抑郁疗效和不良反应 ,以及血药浓度与疗效和不良反应的关系。 方法 8例健康成人进行单次剂量的药代动力学研究。 38例抑郁患者随机接受吗氯贝胺或丙咪嗪治疗。疗效采用汉密顿抑郁量表 ,不良反应采用Asberg副作用量表和实验实检查。同时测定吗氯贝胺的稳态血药浓度。 结果 吗氯贝胺的药代动力学符合一室房室模型 ,疗效与丙咪嗪相似 ,抗胆碱能不良反应较丙咪嗪少。血药浓度与剂量相关 ,与疗效和不良反应无显著相关。 结论 吗氯贝胺是一种有效而安全的抗抑郁药。
Objective To study the pharmacokinetics, antidepressant efficacy and adverse reactions of the new drug, clomipramine, and the relationship between plasma concentration and efficacy and adverse reactions. Methods Eight healthy adults were studied on a single dose pharmacokinetic study. Thirty-eight patients with depression were randomized to receive either moclobemide or imipramine. The efficacy of the Hamilton Depression Scale, adverse reactions using Asberg side effects scale and experimental examination. Simultaneous determination of mocetine steady-state plasma concentration. Results Pharmacokinetics of mocetamine met the one-compartment model of room, with similar efficacy to imipramine and less anticholinergic response than imipramine. Blood concentration and dose-related, and efficacy and adverse reactions no significant correlation. Conclusion Moclobemide is an effective and safe antidepressant.